Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Chugai Succeeds in Establishing World's First Stable Cancer Stem Cell Lines
October 22, 2012
- MTPC to Dissolve Capital Alliance with Choseido
October 22, 2012
- Kyowa Kirin Suspends PIIa Study of RTA 402 in Response to Licensor’s Termination of Study
October 22, 2012
- Nexium Dominates No.1, 2 Positions in Both GP, HP Markets in September Prior to Lifting of Ban on Long-Term Prescription: RepTrack Survey
October 19, 2012
- 40% of Doctors Collect Drug Information Via Smartphones: CareNet Survey
October 19, 2012
- Novartis Files for Additional Indication of Pediatric Use for Xolair
October 18, 2012
- Ajinomoto Files NDA for AJH801, 6th Fixed-Dose ARB/CCB Combination in Japan
October 18, 2012
- Qol’s Mr Takada Hints at Continued Use of Long-Listed Drugs from Makers Hiring Apo Plus MRs
October 17, 2012
- Asklep to Set Up 3rd East Asian Subsidiary in South Korea
October 17, 2012
- Denosumab Significantly Reduces Vertebral Fractures in Osteoporosis Patients in PIII Study: Daiichi Sankyo
October 17, 2012
- Asahi Glass Offers CMO Services to Biopharmaceutical Industry Using ASPEX Technology: Dr Kumagai
October 17, 2012
- MediciNova to Bring Japanese Pharma Synthesized Drug Candidates to the World: Dr Matsuda
October 17, 2012
- Qol to Fully Enter CSO Market thru Apo Plus Acquisition, Mr Takada to Be Director
October 16, 2012
- MTPC’s Oral MS Treatment Charging towards Blockbuster Territory
October 16, 2012
- Hospira Files Public Knowledge-Based Application for Generic Gemcitabine for Malignant Lymphoma
October 16, 2012
- Towa Pharmaceutical Expanding Direct-Sales Network as Its Distributors Face Lack of Successors
October 15, 2012
- Pirespa Debuts in South Korea through Ildong: Shionogi
October 15, 2012
- Long-Term Investments in Developing Countries Expects Returns from 2020: President Naito of Eisai
October 15, 2012
- Radical AD Treatments Hit “PIII Wall” Again, but Amyloid β Hypothesis Remains Unshaken
October 15, 2012
- Meiji Seika Pharma to Solely Market 3 Diagnostics for Infectious Diseases
October 12, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…